NEW YORK (GenomeWeb News) – Arrayit said today it has inked a professional services master agreement with Diagnostic Oncology Research Organization to aid it in obtaining approval from the US Food and Drug Administration for its tests.

The agreement will serve as a blueprint for submitting Arrayit's OvaDx presymptomatic ovarian cancer monitoring and screening test, a secondary Parkinson's disease diagnostic test, and other tests in the company's pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.